Cancer Research The Future of Cancer Research: Science and Patient Impact  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 49, 6365-6368, November 15, 1989]
© 1989 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Holm, C.
Right arrow Articles by Pommier, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holm, C.
Right arrow Articles by Pommier, Y.

Differential Requirement of DNA Replication for the Cytotoxicity of DNA Topoisomerase I and II Inhibitors in Chinese Hamster DC3F Cells

Christine Holm, Joseph M. Covey, Donna Kerrigan and Yves Pommier1

Laboratory of Molecular Pharmacology, Division of Cancer Treatment, Developmental Therapeutics Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892

The cytotoxicity of topoisomerase inhibitors is thought to result from the induction of enzyme-mediated DNA breaks. The fact that these breaks reverse rapidly in cells programmed to die, led us to investigate further the cytotoxic mechanisms of topoisomerase I (camptothecin) and topoisomerase II inhibitors (VP-16 and amsacrine) in Chinese Hamster lung fibroblasts (DC3F). Exposures (30 min) to camptothecin produced limited cell killing with approximately 20% of the cells naturally resistant. This resistance was overcome by increasing the drug exposure time. Inhibition of DNA synthesis by 5-min pretreatments with aphidicolin or hydroxyurea abolished the cytotoxicity of camptothecin without changing the level of camptothecin-induced DNA breaks. A good correlation was found between the degree of DNA synthesis inhibition by aphidicolin and the reduction of camptothecin cytotoxicity. In similar experiments performed with topoisomerase II inhibitors, aphidicolin prevented only partially against VP-16- and amsacrine-induced cytotoxicities, yet had no effect upon drug-induced DNA breaks. These results indicate that the production of topoisomerase-mediated DNA breaks by antitumor drugs is not sufficient for cell killing. Instead, an interference of moving DNA replication forks with drug-stabilized topoisomerase-DNA complexes is critical for cell death. The cytotoxicity of camptothecin seemed to be completely related to this process, while that of topoisomerase II inhibitors seemed to involve additional mechanisms in DC3F cells.

1 To whom requests for reprints should be addressed, at Building 37, Room 5A19, National Cancer Institute, Bethesda, MD 20892.

Received 11/ 9/88. Revised 3/10/89. Revised 5/12/89. Revised 8/11/89. Accepted 8/18/89.




This article has been cited by other articles:


Home page
J. Bacteriol.Home page
J. R. Pohlhaus, D. T. Long, E. O'Reilly, and K. N. Kreuzer
The {varepsilon} Subunit of DNA Polymerase III Is Involved in the Nalidixic Acid-Induced SOS Response in Escherichia coli
J. Bacteriol., August 1, 2008; 190(15): 5239 - 5247.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C.-P. Lin, Y. Ban, Y. L. Lyu, S. D. Desai, and L. F. Liu
A Ubiquitin-Proteasome Pathway for the Repair of Topoisomerase I-DNA Covalent Complexes
J. Biol. Chem., July 25, 2008; 283(30): 21074 - 21083.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
D. A. Koster, F. Czerwinski, L. Halby, A. Crut, P. Vekhoff, K. Palle, P. B. Arimondo, and N. H. Dekker
Single-molecule observations of topotecan-mediated TopIB activity at a unique DNA sequence
Nucleic Acids Res., April 1, 2008; 36(7): 2301 - 2310.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
J. A. Seiler, C. Conti, A. Syed, M. I. Aladjem, and Y. Pommier
The Intra-S-Phase Checkpoint Affects both DNA Replication Initiation and Elongation: Single-Cell and -DNA Fiber Analyses
Mol. Cell. Biol., August 15, 2007; 27(16): 5806 - 5818.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Montaudon, K. Palle, L. P. Rivory, J. Robert, C. Douat-Casassus, S. Quideau, M.-A. Bjornsti, and P. Pourquier
Inhibition of Topoisomerase I Cleavage Activity by Thiol-reactive Compounds: IMPORTANCE OF VICINAL CYSTEINES 504 AND 505
J. Biol. Chem., May 11, 2007; 282(19): 14403 - 14412.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. N. Tse, K. G. Rendahl, T. Sheikh, H. Cheema, K. Aardalen, M. Embry, S. Ma, E. J. Moler, Z. J. Ni, D. E. Lopes de Menezes, et al.
CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons In vitro and In vivo
Clin. Cancer Res., January 15, 2007; 13(2): 591 - 602.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Takemura, V. A. Rao, O. Sordet, T. Furuta, Z.-H. Miao, L. Meng, H. Zhang, and Y. Pommier
Defective Mre11-dependent Activation of Chk2 by Ataxia Telangiectasia Mutated in Colorectal Carcinoma Cells in Response to Replication-dependent DNA Double Strand Breaks
J. Biol. Chem., October 13, 2006; 281(41): 30814 - 30823.
[Abstract] [Full Text] [PDF]


Home page
MutagenesisHome page
S. F. El-Khamisy and K. W. Caldecott
TDP1-dependent DNA single-strand break repair and neurodegeneration
Mutagenesis, July 1, 2006; 21(4): 219 - 224.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C.-C. Kuo, J.-F. Liu, and J.-Y. Chang
DNA Repair Enzyme, O6-Methylguanine DNA Methyltransferase, Modulates Cytotoxicity of Camptothecin-Derived Topoisomerase I Inhibitors
J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 946 - 954.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. D. Gray, M. Mann, J. L. Nitiss, and L. M. Hendershot
Activation of the Unfolded Protein Response Is Necessary and Sufficient for Reducing Topoisomerase II{alpha} Protein Levels and Decreasing Sensitivity to Topoisomerase-Targeted Drugs
Mol. Pharmacol., December 1, 2005; 68(6): 1699 - 1707.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. K. McClendon, A. C. Rodriguez, and N. Osheroff
Human Topoisomerase II{alpha} Rapidly Relaxes Positively Supercoiled DNA: IMPLICATIONS FOR ENZYME ACTION AHEAD OF REPLICATION FORKS
J. Biol. Chem., November 25, 2005; 280(47): 39337 - 39345.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
V. A. Rao, A. M. Fan, L. Meng, C. F. Doe, P. S. North, I. D. Hickson, and Y. Pommier
Phosphorylation of BLM, Dissociation from Topoisomerase III{alpha}, and Colocalization with {gamma}-H2AX after Topoisomerase I-Induced Replication Damage
Mol. Cell. Biol., October 15, 2005; 25(20): 8925 - 8937.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S.-J. Shih, T. Erbele, and A. Y. Chen
Ku86 Modulates DNA Topoisomerase I-Mediated Radiosensitization, but not Cytotoxicity, in Mammalian Cells
Cancer Res., October 15, 2005; 65(20): 9194 - 9199.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Flatten, N. T. Dai, B. T. Vroman, D. Loegering, C. Erlichman, L. M. Karnitz, and S. H. Kaufmann
The Role of Checkpoint Kinase 1 in Sensitivity to Topoisomerase I Poisons
J. Biol. Chem., April 8, 2005; 280(14): 14349 - 14355.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
E. L. Baldwin, A. C. Berger, A. H. Corbett, and N. Osheroff
Mms22p protects Saccharomyces cerevisiae from DNA damage induced by topoisomerase II
Nucleic Acids Res., February 17, 2005; 33(3): 1021 - 1030.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
A. Y. Chen, S.-J. Shih, L. N. Garriques, M. L. Rothenberg, M. Hsiao, and D. P. Curran
Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizer
Mol. Cancer Ther., February 1, 2005; 4(2): 317 - 324.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Yu, E. Khan, M. A. Khaleque, J. Lee, G. Laco, G. Kohlhagen, S. Kharbanda, Y.-C. Cheng, Y. Pommier, and A. Bharti
Phosphorylation of DNA Topoisomerase I by the c-Abl Tyrosine Kinase Confers Camptothecin Sensitivity
J. Biol. Chem., December 10, 2004; 279(50): 51851 - 51861.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. N. Tse and G. K. Schwartz
Potentiation of Cytotoxicity of Topoisomerase I Poison by Concurrent and Sequential Treatment with the Checkpoint Inhibitor UCN-01 Involves Disparate Mechanisms Resulting in Either p53-Independent Clonogenic Suppression or p53-Dependent Mitotic Catastrophe
Cancer Res., September 15, 2004; 64(18): 6635 - 6644.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Loegering, S. J. H. Arlander, J. Hackbarth, B. T. Vroman, P. Roos-Mattjus, K. M. Hopkins, H. B. Lieberman, L. M. Karnitz, and S. H. Kaufmann
Rad9 Protects Cells from Topoisomerase Poison-induced Cell Death
J. Biol. Chem., April 30, 2004; 279(18): 18641 - 18647.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Lupi, G. Matera, D. Branduardi, M. D'Incalci, and P. Ubezio
Cytostatic and Cytotoxic Effects of Topotecan Decoded by a Novel Mathematical Simulation Approach
Cancer Res., April 15, 2004; 64(8): 2825 - 2832.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Rapisarda, B. Uranchimeg, O. Sordet, Y. Pommier, R. H. Shoemaker, and G. Melillo
Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1: Mechanism and Therapeutic Implications
Cancer Res., February 15, 2004; 64(4): 1475 - 1482.
[Abstract] [Full Text] [PDF]


Home page
Eukaryot CellHome page
M. Malik and J. L. Nitiss
DNA Repair Functions That Control Sensitivity to Topoisomerase-Targeting Drugs
Eukaryot. Cell, February 1, 2004; 3(1): 82 - 90.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Interthal, P. M. Quigley, W. G. J. Hol, and J. J. Champoux
The Role of Lysine 532 in the Catalytic Mechanism of Human Topoisomerase I
J. Biol. Chem., January 23, 2004; 279(4): 2984 - 2992.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. P. Goetz, C. Erlichman, A. J. Windebank, J. M. Reid, J. A. Sloan, P. Atherton, A. A. Adjei, J. Rubin, H. Pitot, E. Galanis, et al.
Phase I and Pharmacokinetic Study of Two Different Schedules of Oxaliplatin, Irinotecan, Fluorouracil, and Leucovorin in Patients With Solid Tumors
J. Clin. Oncol., October 15, 2003; 21(20): 3761 - 3769.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
M. Sabourin, J. L. Nitiss, K. C. Nitiss, K. Tatebayashi, H. Ikeda, and N. Osheroff
Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks
Nucleic Acids Res., August 1, 2003; 31(15): 4373 - 4384.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Furuta, H. Takemura, Z.-Y. Liao, G. J. Aune, C. Redon, O. A. Sedelnikova, D. R. Pilch, E. P. Rogakou, A. Celeste, H. T. Chen, et al.
Phosphorylation of Histone H2AX and Activation of Mre11, Rad50, and Nbs1 in Response to Replication-dependent DNA Double-strand Breaks Induced by Mammalian DNA Topoisomerase I Cleavage Complexes
J. Biol. Chem., May 23, 2003; 278(22): 20303 - 20312.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
G. Hong and K. N. Kreuzer
Endonuclease cleavage of blocked replication forks: An indirect pathway of DNA damage from antitumor drug-topoisomerase complexes
PNAS, April 29, 2003; 100(9): 5046 - 5051.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
R. M. Goldberg, S. H. Kaufmann, P. Atherton, J. A. Sloan, A. A. Adjei, H. C. Pitot, S. R. Alberts, J. Rubin, L. L. Miller, and C. Erlichman
A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin
Ann. Onc., October 1, 2002; 13(10): 1674 - 1680.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. Pourquier, C. Gioffre, G. Kohlhagen, Y. Urasaki, F. Goldwasser, L. W. Hertel, S. Yu, R. T. Pon, W. H. Gmeiner, and Y. Pommier
Gemcitabine (2',2'-Difluoro-2'-Deoxycytidine), an Antimetabolite That Poisons Topoisomerase I
Clin. Cancer Res., August 1, 2002; 8(8): 2499 - 2504.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
R. T. Van Dross and M. M. Sanders
Molecular Characterization of Recombinant Pneumocystis carinii Topoisomerase I: Differential Interactions with Human Topoisomerase I Poisons and Pentamidine
Antimicrob. Agents Chemother., July 1, 2002; 46(7): 2145 - 2154.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
Y. Mao, I. R. Mehl, and M. T. Muller
Subnuclear distribution of topoisomerase I is linked to ongoing transcription and p53 status
PNAS, January 17, 2002; (2002) 22631899.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
T. Kobayashi, S. Tada, T. Tsuyama, H. Murofushi, M. Seki, and T. Enomoto
Focus-formation of replication protein A, activation of checkpoint system and DNA repair synthesis induced by DNA double-strand breaks in Xenopus egg extract
J. Cell Sci., January 8, 2002; 115(15): 3159 - 3169.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Ikegami, L. Ha, K. Arimori, P. Latham, K. Kobayashi, S. Ceryak, Y. Matsuzaki, and B. Bouscarel
Intestinal Alkalization As a Possible Preventive Mechanism in Irinotecan (CPT-11)-induced Diarrhea
Cancer Res., January 1, 2002; 62(1): 179 - 187.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. M. Wilstermann and N. Osheroff
Base Excision Repair Intermediates as Topoisomerase II Poisons
J. Biol. Chem., November 30, 2001; 276(49): 46290 - 46296.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Jacob, M. Aguado, D. Fallik, and F. Praz
The Role of the DNA Mismatch Repair System in the Cytotoxicity of the Topoisomerase Inhibitors Camptothecin and Etoposide to Human Colorectal Cancer Cells
Cancer Res., September 1, 2001; 61(17): 6555 - 6562.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
A. Montecucco, R. Rossi, G. Ferrari, A. I. Scovassi, E. Prosperi, and G. Biamonti
Etoposide Induces the Dispersal of DNA Ligase I from Replication Factories
Mol. Biol. Cell, July 1, 2001; 12(7): 2109 - 2118.
[Abstract] [Full Text] [PDF]


Home page
GeneticsHome page
B. A. Stohr and K. N. Kreuzer
Repair of Topoisomerase-Mediated DNA Damage in Bacteriophage T4
Genetics, May 1, 2001; 158(1): 19 - 28.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
A. K. Larsen, C. Gilbert, G. Chyzak, S. Y. Plisov, I. Naguibneva, O. Lavergne, L. Lesueur-Ginot, and D. C. H. Bigg
Unusual Potency of BN 80915, a Novel Fluorinated E-ring Modified Camptothecin, toward Human Colon Carcinoma Cells
Cancer Res., April 1, 2001; 61(7): 2961 - 2967.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
P. Pourquier, J. L. Waltman, Y. Urasaki, N. A. Loktionova, A. E. Pegg, J. L. Nitiss, and Y. Pommier
Topoisomerase I-mediated Cytotoxicity of N-Methyl-N'-nitro-N-nitrosoguanidine: Trapping of Topoisomerase I by the O6-Methylguanine
Cancer Res., January 1, 2001; 61(1): 53 - 58.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
C. Erlichman, S. A. Boerner, C. G. Hallgren, R. Spieker, X.-Y. Wang, C. D. James, G. L. Scheffer, M. Maliepaard, D. D. Ross, K. C. Bible, et al.
The HER Tyrosine Kinase Inhibitor CI1033 Enhances Cytotoxicity of 7-Ethyl-10-hydroxycamptothecin and Topotecan by Inhibiting Breast Cancer Resistance Protein-mediated Drug Efflux
Cancer Res., January 1, 2001; 61(2): 739 - 748.
[Abstract] [Full Text]


Home page
Ann. N. Y. Acad. Sci.Home page
K. W. KOHN and Y. POMMIER
Molecular and Biological Determinants of the Cytotoxic Actions of Camptothecins: Perspective for the Development of New Topoisomerase I Inhibitors
Ann. N.Y. Acad. Sci., December 1, 2000; 922(1): 11 - 26.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
B. C. GIOVANELLA, N. HARRIS, J. MENDOZA, Z. CAO, J. LIEHR, and J. S. STEHLIN
Dependence of Anticancer Activity of Camptothecins on Maintaining Their Lactone Function
Ann. N.Y. Acad. Sci., December 1, 2000; 922(1): 27 - 35.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
P. FIORANI and M.-A. BJORNSTI
Mechanisms of DNA Topoisomerase I-Induced Cell Killing in the Yeast: Saccharomyces cerevisiae
Ann. N.Y. Acad. Sci., December 1, 2000; 922(1): 65 - 75.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
O. LAVERGNE, D. DEMARQUAY, P. G. KASPRZYK, and D. C.H. BIGG
Homocamptothecins: E-Ring Modified CPT Analogues
Ann. N.Y. Acad. Sci., December 1, 2000; 922(1): 100 - 111.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Mao, S. Okada, L.-S. Chang, and M. T. Muller
p53 Dependence of Topoisomerase I Recruitment in Vivo
Cancer Res., August 1, 2000; 60(16): 4538 - 4543.
[Abstract] [Full Text]


Home page
MutagenesisHome page
M. A. Johnson, P. E. Bryant, and N. J. Jones
Isolation of camptothecin-sensitive Chinese hamster cell mutants: phenotypic heterogeneity within the ataxia telangiectasia-like XRCC8 (irs2) complementation group
Mutagenesis, July 1, 2000; 15(4): 367 - 374.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
D. Strumberg, A. A. Pilon, M. Smith, R. Hickey, L. Malkas, and Y. Pommier
Conversion of Topoisomerase I Cleavage Complexes on the Leading Strand of Ribosomal DNA into 5'-Phosphorylated DNA Double-Strand Breaks by Replication Runoff
Mol. Cell. Biol., June 1, 2000; 20(11): 3977 - 3987.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
J. Fertala, J. R. Vance, P. Pourquier, Y. Pommier, and M.-A. Bjornsti
Substitutions of Asn-726 in the Active Site of Yeast DNA Topoisomerase I Define Novel Mechanisms of Stabilizing the Covalent Enzyme-DNA Intermediate
J. Biol. Chem., May 12, 2000; 275(20): 15246 - 15253.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
B. Vladu, J. M. Woynarowski, G. Manikumar, M. C. Wani, M. E. Wall, D. D. Von Hoff, and R. M. Wadkins
7- and 10-Substituted Camptothecins: Dependence of Topoisomerase I-DNA Cleavable Complex Formation and Stability on the 7- and 10-Substituents
Mol. Pharmacol., February 1, 2000; 57(2): 243 - 251.
[Abstract] [Full Text]


Home page
Mol. Cell. Biol.Home page
G. Hong and K. N. Kreuzer
An Antitumor Drug-Induced Topoisomerase Cleavage Complex Blocks a Bacteriophage T4 Replication Fork In Vivo
Mol. Cell. Biol., January 15, 2000; 20(2): 594 - 603.
[Abstract] [Full Text]


Home page
Mol. Cell. Biol.Home page
R. M. Taylor, D. J. Moore, J. Whitehouse, P. Johnson, and K. W. Caldecott
A Cell Cycle-Specific Requirement for the XRCC1 BRCT II Domain during Mammalian DNA Strand Break Repair
Mol. Cell. Biol., January 15, 2000; 20(2): 735 - 740.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
J. A. Simon, P. Szankasi, D. K. Nguyen, C. Ludlow, H. M. Dunstan, C. J. Roberts, E. L. Jensen, L. H. Hartwell, and S. H. Friend
Differential Toxicities of Anticancer Agents among DNA Repair and Checkpoint Mutants of Saccharomyces cerevisiae
Cancer Res., January 1, 2000; 60(2): 328 - 333.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
P. Fiorani, J. F. Amatruda, A. Silvestri, R. H. Butler, M.-A. Bjornsti, and P. Benedetti
Domain Interactions Affecting Human DNA Topoisomerase I Catalysis and Camptothecin Sensitivity
Mol. Pharmacol., December 1, 1999; 56(6): 1105 - 1115.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. J. D. Reid, P. Fiorani, M. Sugawara, and M.-A. Bjornsti
CDC45 and DPB11 are required for processive DNA replication and resistance to DNA topoisomerase I-mediated DNA damage
PNAS, September 28, 1999; 96(20): 11440 - 11445.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. Gobert, A. Skladanowski, and A. K. Larsen
The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53
PNAS, August 31, 1999; 96(18): 10355 - 10360.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. M. Wadkins, P. M. Potter, B. Vladu, J. Marty, G. Mangold, S. Weitman, G. Manikumar, M. C. Wani, M. E. Wall, and D. D. Von Hoff
Water Soluble 20(S)-Glycinate Esters of 10,11-Methylenedioxycamptothecins Are Highly Active against Human Breast Cancer Xenografts
Cancer Res., July 1, 1999; 59(14): 3424 - 3428.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Komatani, M. Morita, N. Sakaizumi, K. Fukasawa, E. Yoshida, A. Okura, T. Yoshinari, and S. Nishimura
A New Mechanism of Acquisition of Drug Resistance by Partial Duplication of Topoisomerase I
Cancer Res., June 1, 1999; 59(11): 2701 - 2708.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Hann, D. L. Evans, J. Fertala, P. Benedetti, M.-A. Bjornsti, and D. J. Hall
Increased Camptothecin Toxicity Induced in Mammalian Cells Expressing Saccharomyces cerevisiae DNA Topoisomerase I
J. Biol. Chem., April 3, 1998; 273(14): 8425 - 8433.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Ohdo, T. Makinosumi, T. Ishizaki, E. Yukawa, S. Higuchi, S. Nakano, and N. Ogawa
Cell Cycle-Dependent Chronotoxicity of Irinotecan Hydrochloride in Mice
J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1383 - 1388.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
P. Pourquier, A. A. Pilon, G. Kohlhagen, A. Mazumder, A. Sharma, and Y. Pommier
Trapping of Mammalian Topoisomerase I and Recombinations Induced by Damaged DNA Containing Nicks or Gaps. IMPORTANCE OF DNA END PHOSPHORYLATION AND CAMPTOTHECIN EFFECTS
J. Biol. Chem., October 17, 1997; 272(42): 26441 - 26447.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. D. Desai, L. F. Liu, D. Vazquez-Abad, and P. D'Arpa
Ubiquitin-dependent Destruction of Topoisomerase I Is Stimulated by the Antitumor Drug Camptothecin
J. Biol. Chem., September 26, 1997; 272(39): 24159 - 24164.
[Abstract] [Full Text] [PDF]